HRP20240453T1 - (+)-azasetron za uporabu u liječenju poremećaja uha - Google Patents
(+)-azasetron za uporabu u liječenju poremećaja uha Download PDFInfo
- Publication number
- HRP20240453T1 HRP20240453T1 HRP20240453TT HRP20240453T HRP20240453T1 HR P20240453 T1 HRP20240453 T1 HR P20240453T1 HR P20240453T T HRP20240453T T HR P20240453TT HR P20240453 T HRP20240453 T HR P20240453T HR P20240453 T1 HRP20240453 T1 HR P20240453T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- hearing loss
- ear
- azazetrone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Pripravak za uporabu u liječenju poremećaja uha koji sadrži (+)-azazetron, formule (R)-I:
[image]
ili njegova farmaceutski prihvatljiva sol i/ili solvat,
i najmanje jedan farmaceutski prihvatljiv ekscipijent,
pri čemu pripravak sadrži najmanje 90: 10 w/w mješavine (+)-azazetrona formule (R)-I:(-)-azazetrona, ili njegovih farmaceutski prihvatljivih soli i/ili solvata.
2. Pripravak za uporabu prema zahtjevu 1, naznačen time što je farmaceutski prihvatljiva sol (+)-azazetrona odabrana između (+)-azazetron besilata, (+)-azazetron malata i (+)-azazetron hidroklorida.
3. Pripravak za uporabu prema zahtjevu 1 ili 2, naznačen time što se pripravak treba primijeniti u dozi u rasponu od oko 0.01 mg do oko 100 mg.
4. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time što se pripravak treba primijeniti sistemski, poželjno oralno.
5. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time što se pripravak primjenjuje lokalno, poželjno izravno u uho, poželjnije je da se pripravak stavi na uređaj koji se umeće u kohlearni kanal ili bilo koji drugi dio pužnice.
6. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time što je poremećaj uha odabran iz skupine koju čine: poremećaj unutarnjeg uha, poremećaj srednjeg uha, poremećaj vanjskog uha, infekcija uha, upala uha i autoimuni poremećaj uha.
7. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time što je poremećaj uha odabran između gubitka sluha, tinitusa i vestibularnog poremećaja.
8. Pripravak za uporabu prema zahtjevu 7, naznačen time što je gubitak sluha senzorineuralni gubitak sluha.
9. Pripravak za uporabu prema zahtjevu 8, naznačen time što je senzorineuralni gubitak sluha senzorineuralni gubitak sluha izazvan ototoksičnim spojem, poželjno senzorineuralni gubitak sluha izazvan platinom, poželjnije senzorineuralni gubitak sluha izazvan cisplatinom.
10. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time što se pripravak treba primijeniti na subjektu kojem je dijagnosticiran rak.
11. Pripravak za uporabu prema zahtjevu 10, naznačen time što subjekt s dijagnosticiranim rakom čeka na primanje ili prima kemoterapiju baziranu na platini, poželjno cisplatinu, karboplatinu, oksaliplatinu ili njihovu kombinaciju.
12. Pripravak za uporabu prema zahtjevu 11, naznačen time što se pripravak treba primijeniti prije, tijekom i/ili nakon kemoterapije bazirane na platini, poželjno kemoterapije bazirane na cisplatinu, karboplatinu ili oksaliplatinu ili njihovoj kombinaciji.
13. Pripravak za uporabu prema zahtjevu 8, naznačen time što je senzorineuralni gubitak sluha iznenadni senzorineuralni gubitak sluha ili senzorineuralni gubitak sluha izazvan bukom.
14. Pripravak za uporabu prema zahtjevu 7, naznačen time što je vestibularni poremećaj lezijski vestibularni poremećaj.
15. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 14, naznačen time što pripravak je pripravak s trenutačnim otpuštanjem ili pripravak s produljenim otpuštanjem.
16. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 15, naznačen time što je pripravak orodisperzibilni pripravak.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322690P | 2016-04-14 | 2016-04-14 | |
| EP16180192 | 2016-07-19 | ||
| EP17717441.4A EP3442537B1 (en) | 2016-04-14 | 2017-04-14 | (+)-azasetron for use in the treatment of ear disorders |
| PCT/EP2017/059058 WO2017178645A1 (en) | 2016-04-14 | 2017-04-14 | (+)-azasetron for use in the treatment of ear disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240453T1 true HRP20240453T1 (hr) | 2024-06-21 |
Family
ID=65588799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240453TT HRP20240453T1 (hr) | 2016-04-14 | 2017-04-14 | (+)-azasetron za uporabu u liječenju poremećaja uha |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11612605B2 (hr) |
| EP (1) | EP4335508A3 (hr) |
| JP (1) | JP7158723B2 (hr) |
| CN (1) | CN109310698B (hr) |
| AU (1) | AU2023202897B2 (hr) |
| CL (1) | CL2018002930A1 (hr) |
| DK (1) | DK3442537T3 (hr) |
| ES (1) | ES2975016T3 (hr) |
| FI (1) | FI3442537T3 (hr) |
| HR (1) | HRP20240453T1 (hr) |
| HU (1) | HUE066000T2 (hr) |
| IL (1) | IL262305B (hr) |
| MX (1) | MX384045B (hr) |
| NZ (1) | NZ747201A (hr) |
| PL (1) | PL3442537T3 (hr) |
| RS (1) | RS65379B1 (hr) |
| SI (1) | SI3442537T1 (hr) |
| ZA (1) | ZA201806894B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056138T2 (hu) * | 2015-05-18 | 2022-01-28 | Sensorion | Azasetron a halláskárosodás kezelésében való felhasználásra |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| US5360800A (en) | 1987-09-03 | 1994-11-01 | Glaxo Group Limited | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
| CA1304082C (en) | 1987-10-22 | 1992-06-23 | Tetsuya Tahara | Benzoxazine compounds and pharmaceutical use thereof |
| GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| GB0009914D0 (en) | 2000-04-20 | 2000-06-07 | Metris Therapeutics Limited | Device |
| GB0104554D0 (en) | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New uses |
| US20030044356A1 (en) | 2001-04-20 | 2003-03-06 | Jin Auh | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) |
| US20030229333A1 (en) * | 2002-02-22 | 2003-12-11 | Control Delivery Systems, Inc. | Methods for treating otic disorders |
| GB0213869D0 (en) | 2002-06-17 | 2002-07-31 | Arakis Ltd | The treatment of pain |
| EP1567163B1 (en) | 2003-01-13 | 2007-04-11 | Dynogen Pharmaceuticals Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
| MY143789A (en) | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
| US20040204466A1 (en) | 2003-04-14 | 2004-10-14 | Orchid Chemicals And Pharmaceuticals Ltd. | Treatment of bronchial asthma using 5-HT3 receptor antagonists |
| US20070265329A1 (en) | 2006-05-12 | 2007-11-15 | Devang Shah T | Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) |
| CA2734139C (en) | 2007-10-02 | 2019-12-24 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| BRPI0915770A2 (pt) | 2008-07-14 | 2015-11-03 | Otonomy Inc | composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos |
| JP5955767B2 (ja) * | 2009-05-20 | 2016-07-20 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬 |
| ES2432618T3 (es) | 2009-05-20 | 2013-12-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular |
| CN101786963B (zh) | 2010-03-03 | 2013-05-08 | 山东众诚药业股份有限公司 | 阿扎司琼中间体的合成方法 |
| US10188695B2 (en) | 2012-02-23 | 2019-01-29 | Sensorion | Calcineurin inhibitors for use in the treatment of lesional vestibular disorders |
| ES2785303T3 (es) | 2012-07-16 | 2020-10-06 | Univ Cornell | Nicotinamida ribósido para tratar la pérdida auditiva |
| BR112016002205A2 (pt) * | 2013-07-31 | 2017-08-01 | Bluepharma Ind Farmaceutica S A | filmes orodispersíveis |
| CN104557906A (zh) | 2015-01-21 | 2015-04-29 | 扬子江药业集团四川海蓉药业有限公司 | 一种盐酸阿扎司琼的制备方法 |
| HUE056138T2 (hu) | 2015-05-18 | 2022-01-28 | Sensorion | Azasetron a halláskárosodás kezelésében való felhasználásra |
-
2017
- 2017-04-14 HU HUE17717441A patent/HUE066000T2/hu unknown
- 2017-04-14 NZ NZ747201A patent/NZ747201A/en unknown
- 2017-04-14 ES ES17717441T patent/ES2975016T3/es active Active
- 2017-04-14 US US16/093,911 patent/US11612605B2/en active Active
- 2017-04-14 RS RS20240412A patent/RS65379B1/sr unknown
- 2017-04-14 JP JP2018553953A patent/JP7158723B2/ja active Active
- 2017-04-14 PL PL17717441.4T patent/PL3442537T3/pl unknown
- 2017-04-14 EP EP23220392.7A patent/EP4335508A3/en not_active Withdrawn
- 2017-04-14 FI FIEP17717441.4T patent/FI3442537T3/fi active
- 2017-04-14 DK DK17717441.4T patent/DK3442537T3/da active
- 2017-04-14 SI SI201731500T patent/SI3442537T1/sl unknown
- 2017-04-14 MX MX2018012587A patent/MX384045B/es unknown
- 2017-04-14 HR HRP20240453TT patent/HRP20240453T1/hr unknown
- 2017-04-14 CN CN201780036585.4A patent/CN109310698B/zh active Active
-
2018
- 2018-10-11 IL IL262305A patent/IL262305B/en unknown
- 2018-10-12 CL CL2018002930A patent/CL2018002930A1/es unknown
- 2018-10-16 ZA ZA2018/06894A patent/ZA201806894B/en unknown
-
2023
- 2023-03-13 US US18/182,511 patent/US20230226071A1/en active Pending
- 2023-05-09 AU AU2023202897A patent/AU2023202897B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3442537T3 (pl) | 2024-07-15 |
| ES2975016T3 (es) | 2024-07-02 |
| AU2023202897B2 (en) | 2025-01-30 |
| CN109310698A (zh) | 2019-02-05 |
| JP7158723B2 (ja) | 2022-10-24 |
| DK3442537T3 (da) | 2024-03-25 |
| ZA201806894B (en) | 2023-03-29 |
| US11612605B2 (en) | 2023-03-28 |
| FI3442537T3 (fi) | 2024-04-04 |
| JP2019513780A (ja) | 2019-05-30 |
| AU2023202897A1 (en) | 2023-05-25 |
| CN109310698B (zh) | 2021-12-24 |
| RS65379B1 (sr) | 2024-04-30 |
| EP4335508A2 (en) | 2024-03-13 |
| HUE066000T2 (hu) | 2024-06-28 |
| EP4335508A3 (en) | 2024-07-10 |
| US20230226071A1 (en) | 2023-07-20 |
| IL262305B (en) | 2022-03-01 |
| MX384045B (es) | 2025-03-14 |
| MX2018012587A (es) | 2019-03-07 |
| NZ747201A (en) | 2023-02-24 |
| SI3442537T1 (sl) | 2024-05-31 |
| IL262305A (en) | 2018-11-29 |
| US20190083503A1 (en) | 2019-03-21 |
| CL2018002930A1 (es) | 2019-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| RU2012139802A (ru) | Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней | |
| AU2015311674B2 (en) | Secnidazole for use in the treatment of bacterial vaginosis | |
| RU2019138166A (ru) | Средство для профилактики или лечения атрофии головного мозга | |
| CN107847489A (zh) | 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂 | |
| RU2016143979A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| RU2020108191A (ru) | Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибиторa циклин-d-киназы | |
| AR108897A1 (es) | Una película de desintegración oral de acción rápida para la administración de anestesia local | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| HRP20240453T1 (hr) | (+)-azasetron za uporabu u liječenju poremećaja uha | |
| JP2016505050A5 (hr) | ||
| MA53368A (fr) | Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale | |
| US10434097B1 (en) | Methods and compositions for treating hearing disorders | |
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| FI3600276T3 (fi) | Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| RU2011113733A (ru) | Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах | |
| JP2019513780A5 (hr) | ||
| RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты | |
| TH1801006398A (th) | (+)-อะซาชีตรอนสำหรับการใช้ในการรักษาความผิดปกติของหู | |
| MX2019004222A (es) | Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias. |